PTPN11 and cancer: Since deficiencies in presenting antigens are linked to resistance against T-cell-triggered tumor elimination, the enhancement of MHC class I expression on tumor cells through SHP2 inhibition offers a valid rationale for synergizing the SHP2 blockade with immunotherapy for cancer patients [12].